Ocera Therapeutics, Inc. has received $-0.35 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.36 while the top line estimate is $-0.33 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -1.47%.
Ocera Therapeutics, Inc. reported better than expected with a surprise EPS of 11.11% or $0.04 during its most recent quarterly earnings. The Actual EPS was $-0.32 compared to the Estimated EPS of $-0.36. Palo Alto based Ocera Therapeutics, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 02, 2017.
In the last quarter, Ocera Therapeutics, Inc. reported Annual Earnings of $-0.32. Based on the filings, last years Annual Earnings was, $-1.33. In the last Quarter, OCRX reported a surprise Earnings per Share of 11.11% . The consensus estimate for current quarter is $-0.35 and for the current fiscal year, the estimate is $-1.38. For the Next fiscal year, the estimate is $-1.11 based on the consensus.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 0.03 points or 5% at $0.57 with 1,824,675 shares getting traded. Post opening the session at $0.65, the shares hit an intraday low of $0.551 and an intraday high of $0.65 and the price was in this range throughout the day. The company has a market cap of $13 million and the number of outstanding shares has been calculated to be 23,143,938 shares. The 52-week high of Ocera Therapeutics, Inc. (NASDAQ:OCRX) is $3.9 and the 52-week low is $0.55.
Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California.